Literature DB >> 17682016

Neurological evaluation of patients with Gaucher disease diagnosed as type 1.

J L Capablo1, A Saenz de Cabezón, J Fraile, P Alfonso, M Pocovi, P Giraldo.   

Abstract

Type 1 Gaucher disease (GD1) is characterised by lack of central nervous system involvement; however, there are several reports of associated neurological manifestations. The aim of this study was to systematically evaluate neurological manifestations in 31 patients with GD1 (12 males and 19 females; mean age 39.4 (range 5-77) years). Participants underwent a complete neurological examination and cognitive tests. Investigation of symptoms and medication intake, and motor and sensory electroneurograms were obtained. 30.7% of adult patients had neurological deficits, including psychomotor delay, parkinsonism, dementia, impaired saccadic ocular movements and peripheral nerve dysfunction. Three patients were redefined as type 3 GD. Electrodiagnosis was performed on 15 patients; 26.7% had reduced amplitude and/or abnormal waveforms in at least three nerves, 33.3% had a mild reduction in amplitude of two nerves and 40% had amplitude reduction in one nerve. Patients with three or more affected nerves had additional neurological symptoms. Our results demonstrate that neurological alterations occur in patients diagnosed with GD1, and subclinical peripheral neuropathy is a frequent finding.

Entities:  

Mesh:

Year:  2007        PMID: 17682016     DOI: 10.1136/jnnp.2006.111518

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  29 in total

1.  The neurological manifestations of Gaucher disease type 1: the French Observatoire on Gaucher disease (FROG).

Authors:  P Chérin; C Rose; C de Roux-Serratrice; D Tardy; D Dobbelaere; B Grosbois; E Hachulla; R Jaussaud; R-M Javier; E Noël; P Clerson; A Hartmann
Journal:  J Inherit Metab Dis       Date:  2010-06-02       Impact factor: 4.982

Review 2.  Juvenile parkinsonism: epidemiology, diagnosis and treatment.

Authors:  Teri R Thomsen; Robert L Rodnitzky
Journal:  CNS Drugs       Date:  2010-06       Impact factor: 5.749

Review 3.  Gaucher disease: the metabolic defect, pathophysiology, phenotypes and natural history.

Authors:  Hagit N Baris; Ian J Cohen; Pramod K Mistry
Journal:  Pediatr Endocrinol Rev       Date:  2014-09

Review 4.  Pathology and current treatment of neurodegenerative sphingolipidoses.

Authors:  Matthias Eckhardt
Journal:  Neuromolecular Med       Date:  2010-08-22       Impact factor: 3.843

5.  A reappraisal of Gaucher disease-diagnosis and disease management algorithms.

Authors:  Pramod K Mistry; Maria Domenica Cappellini; Elena Lukina; Hayri Ozsan; Sara Mach Pascual; Hanna Rosenbaum; Maria Helena Solano; Zachary Spigelman; Jesús Villarrubia; Nora Patricia Watman; Gero Massenkeil
Journal:  Am J Hematol       Date:  2011-01       Impact factor: 10.047

6.  Neurological manifestations in patients with Gaucher disease and their relatives, it is just a coincidence?

Authors:  Pilar Giraldo; Jose Luis Capablo; Pilar Alfonso; Beatriz Garcia-Rodriguez; Paz Latre; Pilar Irun; Alicia Saenz de Cabezon; Miguel Pocovi
Journal:  J Inherit Metab Dis       Date:  2011-03-08       Impact factor: 4.982

7.  The incidence of Parkinsonism in patients with type 1 Gaucher disease: data from the ICGG Gaucher Registry.

Authors:  Barry Rosenbloom; Manisha Balwani; Jeff M Bronstein; Edwin Kolodny; Swati Sathe; Andrea R Gwosdow; John S Taylor; J Alexander Cole; Ari Zimran; Neal J Weinreb
Journal:  Blood Cells Mol Dis       Date:  2010-11-10       Impact factor: 3.039

8.  Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease.

Authors:  Juliane Neumann; Jose Bras; Emma Deas; Sean S O'Sullivan; Laura Parkkinen; Robin H Lachmann; Abi Li; Janice Holton; Rita Guerreiro; Reema Paudel; Badmavady Segarane; Andrew Singleton; Andrew Lees; John Hardy; Henry Houlden; Tamas Revesz; Nicholas W Wood
Journal:  Brain       Date:  2009-03-13       Impact factor: 13.501

Review 9.  Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring.

Authors:  T M Cox; J M F G Aerts; N Belmatoug; M D Cappellini; S vom Dahl; J Goldblatt; G A Grabowski; C E M Hollak; P Hwu; M Maas; A M Martins; P K Mistry; G M Pastores; A Tylki-Szymanska; J Yee; N Weinreb
Journal:  J Inherit Metab Dis       Date:  2008-05-23       Impact factor: 4.982

10.  Evoked potentials and neurocognitive functions in pediatric Egyptian Gaucher patients on enzyme replacement therapy: a single center experience.

Authors:  Azza Abdel Gawad Tantawy; Eman Mounir Sherif; Amira Abdel Moneam Adly; Sahar Hassanine; Amina Hafez Awad
Journal:  J Inherit Metab Dis       Date:  2013-03-19       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.